<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01465386</url>
  </required_header>
  <id_info>
    <org_study_id>2529.00</org_study_id>
    <secondary_id>NCI-2011-03115</secondary_id>
    <nct_id>NCT01465386</nct_id>
  </id_info>
  <brief_title>Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission</brief_title>
  <official_title>A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well bortezomib works in treating patients with high-risk
      acute myeloid leukemia (AML) in remission. Bortezomib may stop the growth of cancer cells by
      blocking some of the enzymes needed for cell growth
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if bortezomib when given as maintenance therapy for six months post-remission
      can improve the progression-free survival (PFS) rate by 50% (or 4.5 months) in first
      remission patients with high-risk AML.

      SECONDARY OBJECTIVES:

      I. To determine the overall survival (OS) after maintenance therapy with bortezomib in first
      remission AML patients.

      II. To assess the safety and tolerability of subcutaneous (SC) administration of bortezomib
      given as maintenance therapy to first remission AML patients.

      OUTLINE:

      Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for
      up to 6 courses in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 4 weeks, every 3 months for
      2 years, and then annually for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed early due to slow enrollment
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">March 2, 2015</completion_date>
  <primary_completion_date type="Actual">January 28, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of days from enrollment to recurrence of acute myeloid leukemia as determined by the reappearance of blasts in the blood or marrow</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome</condition>
  <condition>Adult Acute Minimally Differentiated Myeloid Leukemia (M0)</condition>
  <condition>Adult Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Promyelocytic Leukemia (M3)</condition>
  <condition>Adult Erythroleukemia (M6a)</condition>
  <condition>Adult Pure Erythroid Leukemia (M6b)</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adults with first remission AML including those with prior myelodysplasia
             (MDS)/AML, therapy-related AML, AML with trilineage dysplasia (AML-TLD), and AML with
             adverse cytogenetics

          -  History of histopathologically documented AML that is currently in first remission
             with the presence of 5% or less blasts by morphology and/or flow cytometry from a bone
             marrow aspirate and/or biopsy obtained within 14 days of enrollment

          -  Patients must start therapy between 3-8 weeks after receiving their last prior therapy
             (either induction therapy or consolidation therapy)

          -  Patients may receive up to 4 courses of remission consolidation therapy (e.g.,
             cytarabine) prior to enrollment

          -  Normal kidney and liver function with serum creatinine =&lt; 2.0 mg/dl

          -  Total bilirubin =&lt; 1.5 upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 2.5 x ULN

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Male subjects, even if surgically sterilized (i.e., status postvasectomy) must agree
             to 1 of the following: practice effective barrier contraception during the entire
             study treatment period and through a minimum of 30 days after the last dose of study
             drug, or completely abstain from heterosexual intercourse

          -  Female subject is either postmenopausal for at least 1 year before the screening
             visit, is surgically sterilized or if they are of childbearing potential, agree to
             practice 2 effective methods of contraception from the time of signing the informed
             consent form through 30 days after the last dose of bortezomib, or agree to completely
             abstain from heterosexual intercourse

          -  Understand and voluntarily sign the informed consent form for this study

        Exclusion Criteria:

          -  Favorable AML features defined as the following:

               -  t(8;21)(q22;q22); RUNX1-RUNX1T1

               -  inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

               -  Mutated NPM1 without FLT3-ITD (normal karyotype)

               -  Mutated CEBPA (normal karyotype)

          -  Persistent clinically significant non-hematological toxicity that is &gt; Grade 1 by
             National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
             v4 from prior chemotherapy

          -  Active uncontrolled infection

          -  Known infection with human immunodeficiency virus (HIV)

          -  Medical condition, serious concurrent illness, or other extenuating circumstance that,
             in the judgment of the Principal Investigator, could jeopardize patient safety or
             interfere with the objectives of the study

          -  Uncontrolled or significant cardiovascular disease, including:

               -  Uncontrolled angina or myocardial infarction within 6 months

               -  Current or history of congestive heart failure New York Heart Association (NYHA)
                  class 3 or 4, unless a screening echocardiogram (ECHO) or Multiple Gate
                  Acquisition Scan (MUGA) performed within 1 month prior to study screening results
                  in a left ventricular ejection fraction (LVEF) that is &gt;= 45% (or institutional
                  lower limit of normal value)

               -  Prolonged QTc interval (&gt; 450 msec)

          -  Diagnosed or treated for another malignancy within 3 years of enrollment, with the
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy

          -  Patient has a platelet count of &lt; 30,000 within 3 days before enrollment

          -  Patient has an absolute neutrophil count of &lt; 300 within 3 days before enrollment

          -  Patient has &gt;= Grade 2 peripheral neuropathy

          -  Patient has hypersensitivity to bortezomib, boron, or mannitol

          -  Female patients who are lactating or have a positive urine pregnancy test during the
             screening; pregnancy testing is not required for postmenopausal or surgically
             sterilized women

          -  Participation in clinical trials with other investigational agents not included in
             this trial, within 14 days of the start of this trial and throughout the duration of
             this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Pagel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>November 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2011</study_first_posted>
  <results_first_submitted>February 17, 2017</results_first_submitted>
  <results_first_submitted_qc>February 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treated Patients</title>
          <description>Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
bortezomib: Given SC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
bortezomib: Given SC</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" lower_limit="61" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Number of days from enrollment to recurrence of acute myeloid leukemia as determined by the reappearance of blasts in the blood or marrow</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Patient who began maintenance treatment with bortezomib after induction of remission</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients</title>
            <description>Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
bortezomib: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Number of days from enrollment to recurrence of acute myeloid leukemia as determined by the reappearance of blasts in the blood or marrow</description>
          <population>Patient who began maintenance treatment with bortezomib after induction of remission</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" lower_limit="14" upper_limit="575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
bortezomib: Given SC</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholechystitis</sub_title>
                <description>Serious as required hospitalization, but not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <description>Serious as required hospitalization, but not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral neuropathy</sub_title>
                <description>Grade 2 peripheral neuropathy, a known adverse effect of study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Difficulty finding patients willing or available to come in to clinic for weekly injections for the duration of the study. Study was ultimately closed because of slow enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elihu Estey, MD</name_or_title>
      <organization>FHCRC</organization>
      <phone>206-288-7176</phone>
      <email>eestey@seattlecca.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

